Update on antiretroviral therapy.
Combination antiretroviral treatment (cART) has been highly successful in preventing mother to child transmission of human immunodeficiency virus (HIV) and in reducing mortality and morbidity in HIV infected children. cART is now recommended for all HIV infected infants and selected older children. As these children will need to take cART until adulthood, the aim is to use cART with low risks of virological failure, resistance and toxicity. Since increasing numbers of antiretroviral drugs are becoming available for children, ongoing studies are needed to determine the correct doses for children, to improve adherence and to assess potential toxicity and drug interactions (such as between ritonavir and inhaled fluticasone).
Riordan
A
A
Department of Paediatric Infectious Diseases, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. andrew.riordan@alderhey.nhs.uk
Bugembe
T
T
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D010349:Patient Compliance; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019562:Viral Load
D044966:Anti-Retroviral Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors